Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund
January 21, 2020 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that it has entered into a securities...
Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance
January 07, 2020 07:00 ET
|
Kamada Ltd.
Full-Year 2019 Revenue Expected to be Between $126.5 Million and $127.5 Million, in-line with Company’s Prior Revenue Guidance Company Expects Full-Year 2020 Total Revenue to be Between $132...
Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency
December 16, 2019 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in...
Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product
December 09, 2019 07:00 ET
|
Kamada Ltd.
Commercial supply of the 12-year contract manufacturing agreement, following the completion of the required tech-transfer project, is expected to commence in early 2023Based on current market sales...
Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel
December 02, 2019 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company,...
Kamada Reports Financial Results for Third Quarter and First Nine Months of 2019
November 13, 2019 07:00 ET
|
Kamada Ltd.
Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective Periods in 2018.As a...
Kamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13
November 07, 2019 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for...
Kamada and Kedrion Biopharma Announce Publication of Results from the Registration Study of KEDRAB® (Rabies Immune Globulin [Human]) in Human Vaccines & Immunotherapeutics Medical Journal
October 29, 2019 08:00 ET
|
Kamada Ltd.
The Successful Study was Basis for U.S. Food & Drug Administration Approval of KEDRAB® in 2017 Post-Marketing U.S. Pediatric Study Data Expected in 2H ‘2020 Abstract will be Presented at the...
Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference
September 24, 2019 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer,...
Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda
September 03, 2019 07:00 ET
|
Kamada Ltd.
Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and...